Abstract:Abstract This study aimed to determine impact of chronic conditions on the quality of life (QoL) of patients and their family members. A cross-sectional correlational study was undertaken in the Bahamas and Wales, involving patients aged > 18 years with psoriasis, acne, eczema and hidradenitis suppurativa. Patients in both countries completed the Dermatology Life Quality Index (DLQI). In the Bahamas, children (aged 4–16 years) also completed the Children’s DLQI (CDLQI). Family members (> 18 years) completed the Family Reported Outcome Measure (FROM)-16 and the Family DLQI (FDLQI). Patients in the Bahamas with other chronic conditions (rheumatoid arthritis, diabetes mellitus and chronic kidney disease) completed the WHOQOL-BREF, and children (4–16 years) completed the KINDLR. Their family members (> 18 years) completed FROM-16. The 436 participants were from Wales (20%) and the Bahamas (80%). Of the 203 adult patients, 74% identified as Black, 21% as White and 5% as mix, multiple ethnic groups or other. Of 218 family members, 77% identified as Black, 19% as White, and 4% as mix, multiple ethnic groups or other. In Wales the mean DLQI score was 13.8 (SD 7.7, n = 44), indicating very large impact on QoL. Family members’ FROM-16 mean score was 8.7 (SD 6.7, n = 44), indicating moderate effect on QoL. The FDLQI mean score was 7.7 (SD 6.7, n = 44). DLQI and FDLQI scores [rsp = 0.61, P (two-tailed) = 0.01, n = 88] and DLQI and FROM-16 scores [rsp = 0.59, P (two-tailed) = 0.01, n = 88] were strongly positively correlated. FROM-16 and FDLQI scores were very strongly positively correlated [rsp = 0.74, P (two-tailed) = 0.01, n = 44]. In the Bahamas the mean DLQI score was 7.4 (SD 5, n = 34), indicating moderate impact on QoL. The FROM-16 mean score for family members of adult patients was 3.5 (SD 4.5, n = 45), indicating small effect on QoL. The FDLQI mean score was 3.0 (SD 3.7, n = 45). DLQI and FDLQI scores [rsp = 0.34, P (two-tailed) = 0.05, n = 68] were moderately positively correlated. FROM-16 and FDLQI scores were strongly positively correlated [rsp = 0.61, P (two-tailed) < 0.001, n = 45]. Children’s mean CDLQI score was 7 (SD 4.3, n = 11), indicating moderate effect on QoL. Their family members’ mean FROM-16 score was 3.1 (SD 2.4, n = 11), indicating small impact. The FDLQI mean score was 3.6 (SD 4.4, n = 11). The CDLQI and FDLQI [rsp = 0.60, P (two-tailed) = 0.05, n = 22] and CDLQI and FROM-16 personal/social domain scores [rsp = 0.67, P (two-tailed) = 0.03, n = 22] were strongly positively correlated. FROM-16 and FDLQI scores [rsp = 0.72, P (two-tailed) < 0.01, n = 11] were strongly positively correlated. The mean WHOQOL-BREF for other chronic conditions was 56.4 (SD 8.9, n = 125) and the mean KINDLR score was 74.5 (SD 12.5, n = 4). Their family members’ FROM-16 mean score was 6.3 (SD 5.5, n = 129), indicating small impact on QoL. The WHOQOL-BREF and FROM-16 scores [rsp = −0.28, P (two-tailed) = 0.001] were weakly negatively correlated. Validated QoL questionnaires can be used to measure impact on QoL in different countries. Family members experience a substantial impact on QoL. Skin disease can impact the QoL of family members just as much as family members of people with other noncutaneous chronic diseases. The data provide a challenge to clinicians to identify severely affected family members and assist them further.

The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1

Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1

Impact of neurofibromatosis type 1 on quality of life using the Skindex-29 questionnaire quality of life in NF1

Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey

Quality of Life in Children with Neurofibromatosis Type 1: Agreement between Parents and Patients, and the Role of Disease Severity and Visibility

Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire

Quality of life in patients with neurofibromatosis type 1 and 2 in Canada

Quality of life of patients with neurodermatitis

Neuropsychiatric Manifestations, Reduced Self-Esteem and Poor Quality of Life in Children and Adolescents with Neurofibromatosis Type 1 (NF1): The Impact of Symptom Visibility and Bullying Behavior

Health-related quality of life in patients with neurofibromatosis 1 in Japan: A questionnaire survey using EQ-5D-5L

The impact of mental health on health-related quality of life in patients with NF2-related Schwannomatosis

Quality of life and neurological symptoms in patients with neurofibromatosis type 2: a national database study in Japan

Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas

Evaluation of Quality of Life and Treatment Satisfaction in Newly Diagnosed Cutaneous T-Cell Lymphoma Patients

The impact of a virtual mind–body program on symptoms of depression and anxiety among international English‐speaking adults with neurofibromatosis

Satisfaction from surgical treatment and its influence on the wellbeing of patients with Recklinghausen disease - preliminary report

A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials

Long-term distress throughout one's life: health-related quality of life, economic and caregiver burden of patients with neurofibromatosis type 1 in China

Parent-child discrepancies in reports of child psychosocial functioning in neurofibromatosis type 1

GD09 GD10 Impact of chronic conditions on the quality of life of patients and their family members

Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis